🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The primary objective was to evaluate the persistence of bactericidal antib...
Status
Completed
Location
Alabama Clinical Therapeutics 806 St. Vincent's Drive, Suite 615
Start Date
2010-07
Trial ID
NCT01148017
Treatments Being Tested
The purpose/aim of this study is to assess the safety and antibody response...
Status
Completed
Location
GSK Investigational Site
Start Date
2016-12-08
Trial ID
NCT02986854
The aim of this study is to determine the immunologic noninferiority of Men...
Status
Completed
Location
Alabama Clinical Therapeutics, LLC, Birmington Pediatric Assocaites
Start Date
2020-06-17
Trial ID
NCT04440163
Treatments Being Tested
In this extension study, V59P20E1, the sponsor was planning to assess 5-yea...
Status
Completed
Location
82 Children s Inv Research Prgm (ChIRP) 2900 Medical Center Parkway, Ste. 300
Start Date
2013-05
Trial ID
NCT01823536
Treatments Being Tested
The purpose of the study was to assess the immunogenicity and safety of two...
Status
Completed
Location
06 Kosin University Gospel Hospital 34, amnam-dong
Start Date
2013-11
Trial ID
NCT01973218
The goal of this clinical trial is to determine the immunogenicity of certa...
Status
Recruiting
Location
Emory Children's Center-Vaccine Research Clinic
Start Date
2025-11-04
Trial ID
NCT07197762
This study will evaluate the safety and immunogenicity of combination vacci...
Status
Completed
Location
Alabama Clinical Therapeutics, 806 St. Vincent's Drive, Suite 615
Start Date
2011-08
Trial ID
NCT01272180
Treatments Being Tested
This study will evaluate safety, tolerability, and immunogenicity of a boos...
Status
Completed
Location
CESFAM Gabriela Mistral:
Start Date
2011-07
Trial ID
NCT01367158
The purpose of this study was to evaluate the effectiveness of 2 doses or 3...
Status
Completed
Location
GSK Investigational Site
Start Date
2020-08-14
Trial ID
NCT04502693
This study is examining safety and immunogenicity of 2 doses of Trumenba ad...
Status
Completed
Location
Alabama Clinical Therapeutics, LLC
Start Date
2017-04-24
Trial ID
NCT03135834
Treatments Being Tested